Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies in MPNs; Role of novel mutations in MPN pathogenesis and outcome; Role of JAK inhibitors in MPN treatment; Animal Models of MPNs; and Role of Germline Genetic Factors in MPN Pathogenesis.
By Ross Levine, MD, Memorial SloHuman Oncology and Pathogenesis Program.
Department of Medicine, Leukemia Service,
Memorial Sloan Kettering Cancer Center,
New York, New York, USA.an-Kettering Cancer Center